FDA Pushed Back Intercept Pharma's (ICPT) PDUFA Date; Seeks More Data - Baird Maintains Outperform
Tweet Send to a Friend
Baird maintained an Outperform rating and $346.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the company's announcement that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
